Antibodies against CD73 and uses thereof

US10100129B2 · kind B2 · utility

Assignee

• Bristol-Myers Squibb Company · US

Inventors

• Nils Lonberg · Woodside, US
• Alan J. Korman · Piedmont, US
• Bryan C. BARNHART · San Francisco, US
• Aaron P. YAMNIUK · Lawrenceville, US
• Mohan Srinivasan · Cupertino, US
• Karla A. HENNING · Milpitas, US
• Ming Lei · Princeton, US
• Emanuela Sega · Cupertino, US
• Angela Goodenough · Levittown, US
• Maria Jure-Kunkel · Plainsboro, US
• Guodong Chen · East Brunswick Township, US
• John S. Sack · Lawrenceville, US
• Richard Y. Huang · Princeton, US
• Martin J. Corbett · Mount Holly, US
• Joseph E. Myers, Jr. · Edison, US
• Liang Schweizer · Shanghai, CN
• Sandra V. HATCHER · Fryeburg, US
• Haichun Huang · Fremont, US
• Pingping Zhang · Cupertino, US

Key dates

• Filing date: Nov 19, 2015
• Grant date: Oct 16, 2018
• Expiry date: Nov 19, 2035

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2333/916
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure provides isolated monoclonal antibodies, particularly human antibodies, that bind to human Cluster of Differentiation 73 (CD73) with high affinity, and inhibit the activity of CD73, and optionally mediate antibody dependent CD73 internalization. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for inhibiting the growth of a tumor cell expressing CD73 using the antibodies of the disclosure, including methods for treating various cancers.